How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Melanoma Skin Cancer Diagnostic Testing Market
- By Test Type: Histopathology, Immunohistochemistry (IHC), Molecular Diagnostic Tests, Genetic Testing, Imaging Techniques
- By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), Microarray Analysis, Digital Dermoscopy
- By End User: Hospitals, Diagnostic Laboratories, Specialty Clinics, Research Institutes, Ambulatory Surgical Centers
- By Application: Early Detection, Prognostic Testing, Therapeutic Monitoring, Recurrence Detection, Risk Assessment
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Histopathology leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Melanoma Skin Cancer Diagnostic Testing Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Technology 5
End User 5
Application 5
Companies profiled
Roche Diagnostics
Abbott Laboratories
Thermo Fisher Scientific
QIAGEN
Becton Dickinson and Company (BD)
Hologic Inc.
Myriad Genetics Inc.
Guardant Health Inc.
NanoString Technologies Inc.
BioMérieux SA
Agilent Technologies Inc.
Illumina Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →QIAGEN
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Myriad Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Guardant Health Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →NanoString Technologies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →BioMérieux SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Agilent Technologies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Illumina Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Genomic Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Inc. (Exact Sciences)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Natera
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,095M by 2033 · 9.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Histopathology46.2
- Immunohistochemistry (IHC)12.6
- Molecular Diagnostic Tests15.2
- Genetic Testing13.2
- Imaging Techniques12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,578M → $3,308M · 9.7%
Europe$1,100M → $2,349M · 9.9%
Asia Pacific$1,004M → $2,054M · 9.4%
Latin America$621.8M → $1,456M · 11.2%
Middle East and Africa$478.3M → $970.7M · 9.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.742026
9.752027
9.762028
9.772029
9.782030
9.812031
9.812032
9.822033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics10.0
- Abbott Laboratories15.7
- Thermo Fisher Scientific11.7
- QIAGEN12.6
- Becton Dickinson and Company (BD)13.2
- Hologic Inc.8.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type31.1%
Technology28.0%
End User25.2%
Application15.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.6
- Europe23.2
- Asia Pacific20.3
- Latin America14.4
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 98 | 99 | 83 | 74 | 80 | 78 | 85 |
| Abbott Laboratories | 89 | 75 | 74 | 83 | 72 | 68 | 77 |
| Thermo Fisher Scientific | 64 | 63 | 63 | 71 | 70 | 66 | 66 |
| QIAGEN | 64 | 66 | 71 | 79 | 78 | 81 | 73 |
| Becton Dickinson and Company (BD) | 60 | 65 | 73 | 60 | 68 | 63 | 65 |
| Hologic Inc. | 50 | 50 | 65 | 53 | 54 | 54 | 54 |
| Myriad Genetics Inc. | 51 | 59 | 40 | 56 | 65 | 42 | 52 |
| Guardant Health Inc. | 52 | 49 | 47 | 38 | 59 | 53 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Abbott Laboratories | ✓ | ◐ | − | ✓ | ◐ | ◐ |
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| QIAGEN | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Becton Dickinson and Company (BD) | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Hologic Inc. | − | ◐ | − | − | ◐ | − |
| Myriad Genetics Inc. | ◐ | − | − | − | ◐ | ◐ |
| Guardant Health Inc. | ◐ | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics85
2Abbott Laboratories77
3QIAGEN73
4Thermo Fisher Scientific66
5Becton Dickinson and Company (BD)65
6Hologic Inc.54
7Myriad Genetics Inc.52
8Guardant Health Inc.50
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Abbott LaboratoriesQIAGEN
Contender2
Focused players with pockets of strength.
Thermo Fisher ScientificBecton Dickinson and Company (BD)
Niche3
Specialists in a single segment or region.
Hologic Inc.Myriad Genetics Inc.Guardant Health Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Melanoma Skin Cancer Diagnostic Testing Market — a $321M beachhead inside a $4.48B market.
Beachhead (SOM)$321Mobtainable near-term
Serviceable (SAM)$1.86Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Histopathology
Best fit — highest urgency & budget in Test Type.
Economic buyer76 fit
Immunohistochemistry (IHC)
Strong fit — clear ROI and a fast path to value.
End user67 fit
Molecular Diagnostic Tests
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel30%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Melanoma Skin Cancer Diagnostic Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation12%
Closed-won7%
$18.5KCAC
$70KLTV
3.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Melanoma Skin Cancer Diagnostic Testing Market is a high-growth opportunity — $7.77B by 2033, compounding at 11.6%.
TAM · 2025$3.24Btoday
TAM · 2033$7.77Bforecast
CAGR11.6%2027–2033
Cumulative$47.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.77BTotal addressable market
SAM$3.18BServiceable available market
SOM$568MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.6% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.77BLarge & growingTAM by 2033 at 11.6% CAGR
$3.18BServiceable nowreachable with today’s model
$568MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.06BBear7.5% CAGR
$7.77BBase11.6% CAGR
$9.94BBull15.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Melanoma Skin Cancer Diagnostic Testing Market — a $6.89B market by 2033. Plan: grow share from 10.6% to 16.7%.
Market size · 2033$6.89Btotal addressable
Market CAGR4.1%2027–2033
Target share16.7%from 10.6% today
Revenue ambition$1.15Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 16.7% | At risk |
| Revenue | $703M | $1.15B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.1% | 44.7% | On track |
| Customer retention | 88.4% | 95.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $127M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Melanoma Skin Cancer Diagnostic Testing Market conversation — a $3.53B market you can size, segment and defend in minutes.
Market size · 2033$3.53Btotal opportunity
Growth9.4%CAGR to 2033
Addressable buyers1,296+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 3 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Roche DiagnosticsAbbott LaboratoriesThermo Fisher ScientificQIAGENBecton Dickinson and Company (BD)Hologic Inc.Myriad Genetics Inc.Guardant Health Inc.+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Melanoma Skin Cancer Diagnostic Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Melanoma Skin Cancer Diagnostic Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Melanoma Cancer Diagnostics Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportMelanin Level Skin Analysis System Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMEK2 Antibody Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportMeidical Grade Potassium Sulphate Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportMeidcal Blood Glucose Strips and Meter Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMeibomian Gland Thermal Pulse Therapy Instrument Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMeibomian Gland Dysfunction Treatment Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportMeglumine Diatrizoate Injection Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMeglumine Adenosine Cyclophosphate Injection Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportMeglinitide Market
Market size, share, segmentation and regional forecast.
$753M market · 2025 base year
View reportMegestrol Acetate API Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMegacolon Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.